nodes	percent_of_prediction	percent_of_DWPC	metapath
Trimipramine—ABCB1—Mitomycin—urinary bladder cancer	0.133	0.309	CbGbCtD
Trimipramine—ADRA1B—vas deferens—urinary bladder cancer	0.062	0.395	CbGeAlD
Trimipramine—CYP3A4—Thiotepa—urinary bladder cancer	0.0603	0.14	CbGbCtD
Trimipramine—ABCB1—Gemcitabine—urinary bladder cancer	0.0382	0.0888	CbGbCtD
Trimipramine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0337	0.0783	CbGbCtD
Trimipramine—CYP2C9—Cisplatin—urinary bladder cancer	0.0286	0.0665	CbGbCtD
Trimipramine—ABCB1—Cisplatin—urinary bladder cancer	0.0278	0.0645	CbGbCtD
Trimipramine—ABCB1—Etoposide—urinary bladder cancer	0.0273	0.0634	CbGbCtD
Trimipramine—ABCB1—Doxorubicin—urinary bladder cancer	0.0186	0.0432	CbGbCtD
Trimipramine—ABCB1—Methotrexate—urinary bladder cancer	0.018	0.0419	CbGbCtD
Trimipramine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0175	0.0407	CbGbCtD
Trimipramine—CYP3A4—Etoposide—urinary bladder cancer	0.0163	0.038	CbGbCtD
Trimipramine—CYP3A4—Doxorubicin—urinary bladder cancer	0.0111	0.0259	CbGbCtD
Trimipramine—CYP2C19—urine—urinary bladder cancer	0.00878	0.0558	CbGeAlD
Trimipramine—CYP2C9—urine—urinary bladder cancer	0.0068	0.0433	CbGeAlD
Trimipramine—HTR2A—urine—urinary bladder cancer	0.0056	0.0357	CbGeAlD
Trimipramine—CYP3A4—urine—urinary bladder cancer	0.00519	0.033	CbGeAlD
Trimipramine—CYP2D6—urine—urinary bladder cancer	0.00511	0.0325	CbGeAlD
Trimipramine—ADRA1B—renal system—urinary bladder cancer	0.00378	0.024	CbGeAlD
Trimipramine—ADRA1A—prostate gland—urinary bladder cancer	0.00311	0.0198	CbGeAlD
Trimipramine—Benzphetamine—POR—urinary bladder cancer	0.00272	0.338	CrCbGaD
Trimipramine—HRH1—prostate gland—urinary bladder cancer	0.00241	0.0153	CbGeAlD
Trimipramine—ADRA2A—prostate gland—urinary bladder cancer	0.00237	0.0151	CbGeAlD
Trimipramine—Carbamazepine—UGT2B7—urinary bladder cancer	0.00233	0.29	CrCbGaD
Trimipramine—HTR1A—renal system—urinary bladder cancer	0.0023	0.0146	CbGeAlD
Trimipramine—ADRA1A—epithelium—urinary bladder cancer	0.00229	0.0145	CbGeAlD
Trimipramine—HTR1D—female reproductive system—urinary bladder cancer	0.00221	0.0141	CbGeAlD
Trimipramine—HTR2C—female reproductive system—urinary bladder cancer	0.00219	0.0139	CbGeAlD
Trimipramine—ADRA1A—renal system—urinary bladder cancer	0.00212	0.0135	CbGeAlD
Trimipramine—SLC6A4—female reproductive system—urinary bladder cancer	0.00208	0.0132	CbGeAlD
Trimipramine—ADRA2A—seminal vesicle—urinary bladder cancer	0.002	0.0127	CbGeAlD
Trimipramine—Benazepril—MTHFR—urinary bladder cancer	0.00198	0.246	CrCbGaD
Trimipramine—SLC6A2—female reproductive system—urinary bladder cancer	0.00183	0.0116	CbGeAlD
Trimipramine—HRH1—epithelium—urinary bladder cancer	0.00177	0.0113	CbGeAlD
Trimipramine—HRH1—smooth muscle tissue—urinary bladder cancer	0.00171	0.0109	CbGeAlD
Trimipramine—HRH1—urethra—urinary bladder cancer	0.00161	0.0103	CbGeAlD
Trimipramine—ADRA2A—urethra—urinary bladder cancer	0.00158	0.0101	CbGeAlD
Trimipramine—CYP2C19—vagina—urinary bladder cancer	0.00156	0.0099	CbGeAlD
Trimipramine—HTR2A—epithelium—urinary bladder cancer	0.00148	0.00941	CbGeAlD
Trimipramine—HTR2A—smooth muscle tissue—urinary bladder cancer	0.00142	0.00906	CbGeAlD
Trimipramine—HTR2A—renal system—urinary bladder cancer	0.00137	0.00872	CbGeAlD
Trimipramine—CYP2C9—female reproductive system—urinary bladder cancer	0.00133	0.00848	CbGeAlD
Trimipramine—ABCB1—prostate gland—urinary bladder cancer	0.00132	0.00839	CbGeAlD
Trimipramine—HRH1—female reproductive system—urinary bladder cancer	0.00131	0.00837	CbGeAlD
Trimipramine—ADRA2A—female reproductive system—urinary bladder cancer	0.00129	0.00822	CbGeAlD
Trimipramine—CYP3A4—renal system—urinary bladder cancer	0.00127	0.00808	CbGeAlD
Trimipramine—CYP2D6—renal system—urinary bladder cancer	0.00125	0.00795	CbGeAlD
Trimipramine—HRH1—vagina—urinary bladder cancer	0.00119	0.00757	CbGeAlD
Trimipramine—ADRA2A—vagina—urinary bladder cancer	0.00117	0.00743	CbGeAlD
Trimipramine—ABCB1—seminal vesicle—urinary bladder cancer	0.00112	0.00709	CbGeAlD
Trimipramine—HTR2A—female reproductive system—urinary bladder cancer	0.0011	0.00699	CbGeAlD
Trimipramine—SLC6A2—lymph node—urinary bladder cancer	0.00107	0.0068	CbGeAlD
Trimipramine—Clomipramine—GSTP1—urinary bladder cancer	0.00103	0.127	CrCbGaD
Trimipramine—CYP3A4—female reproductive system—urinary bladder cancer	0.00102	0.00647	CbGeAlD
Trimipramine—CYP2D6—female reproductive system—urinary bladder cancer	0.001	0.00637	CbGeAlD
Trimipramine—HTR2A—vagina—urinary bladder cancer	0.000993	0.00632	CbGeAlD
Trimipramine—ABCB1—epithelium—urinary bladder cancer	0.000969	0.00616	CbGeAlD
Trimipramine—ABCB1—renal system—urinary bladder cancer	0.000899	0.00572	CbGeAlD
Trimipramine—ABCB1—urethra—urinary bladder cancer	0.000883	0.00562	CbGeAlD
Trimipramine—HRH1—lymph node—urinary bladder cancer	0.000769	0.00489	CbGeAlD
Trimipramine—ADRA2A—lymph node—urinary bladder cancer	0.000756	0.00481	CbGeAlD
Trimipramine—ABCB1—female reproductive system—urinary bladder cancer	0.00072	0.00458	CbGeAlD
Trimipramine—Constipation—Thiotepa—urinary bladder cancer	0.000717	0.00233	CcSEcCtD
Trimipramine—Discomfort—Fluorouracil—urinary bladder cancer	0.000715	0.00233	CcSEcCtD
Trimipramine—Purpura—Epirubicin—urinary bladder cancer	0.000712	0.00232	CcSEcCtD
Trimipramine—Vascular purpura—Doxorubicin—urinary bladder cancer	0.00071	0.00231	CcSEcCtD
Trimipramine—Oedema—Gemcitabine—urinary bladder cancer	0.000705	0.0023	CcSEcCtD
Trimipramine—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.000701	0.00228	CcSEcCtD
Trimipramine—Confusional state—Fluorouracil—urinary bladder cancer	0.000699	0.00228	CcSEcCtD
Trimipramine—Convulsion—Cisplatin—urinary bladder cancer	0.000698	0.00227	CcSEcCtD
Trimipramine—Oedema—Fluorouracil—urinary bladder cancer	0.000693	0.00226	CcSEcCtD
Trimipramine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000691	0.00225	CcSEcCtD
Trimipramine—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00069	0.00225	CcSEcCtD
Trimipramine—Ataxia—Methotrexate—urinary bladder cancer	0.00069	0.00225	CcSEcCtD
Trimipramine—Ill-defined disorder—Etoposide—urinary bladder cancer	0.000685	0.00223	CcSEcCtD
Trimipramine—Anxiety—Cisplatin—urinary bladder cancer	0.000683	0.00222	CcSEcCtD
Trimipramine—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000679	0.00221	CcSEcCtD
Trimipramine—Discomfort—Cisplatin—urinary bladder cancer	0.000677	0.00221	CcSEcCtD
Trimipramine—Tachycardia—Fluorouracil—urinary bladder cancer	0.000677	0.0022	CcSEcCtD
Trimipramine—Anorexia—Gemcitabine—urinary bladder cancer	0.000672	0.00219	CcSEcCtD
Trimipramine—Urticaria—Thiotepa—urinary bladder cancer	0.000666	0.00217	CcSEcCtD
Trimipramine—Malaise—Etoposide—urinary bladder cancer	0.000665	0.00217	CcSEcCtD
Trimipramine—Abdominal pain—Thiotepa—urinary bladder cancer	0.000663	0.00216	CcSEcCtD
Trimipramine—Body temperature increased—Thiotepa—urinary bladder cancer	0.000663	0.00216	CcSEcCtD
Trimipramine—Anorexia—Fluorouracil—urinary bladder cancer	0.000661	0.00215	CcSEcCtD
Trimipramine—Purpura—Doxorubicin—urinary bladder cancer	0.000659	0.00215	CcSEcCtD
Trimipramine—Hypotension—Gemcitabine—urinary bladder cancer	0.000659	0.00215	CcSEcCtD
Trimipramine—Oedema—Cisplatin—urinary bladder cancer	0.000657	0.00214	CcSEcCtD
Trimipramine—ABCB1—vagina—urinary bladder cancer	0.000651	0.00414	CbGeAlD
Trimipramine—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.000648	0.00211	CcSEcCtD
Trimipramine—Hypotension—Fluorouracil—urinary bladder cancer	0.000648	0.00211	CcSEcCtD
Trimipramine—Ataxia—Epirubicin—urinary bladder cancer	0.000646	0.0021	CcSEcCtD
Trimipramine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000643	0.0021	CcSEcCtD
Trimipramine—Tachycardia—Cisplatin—urinary bladder cancer	0.000641	0.00209	CcSEcCtD
Trimipramine—Convulsion—Etoposide—urinary bladder cancer	0.000639	0.00208	CcSEcCtD
Trimipramine—Insomnia—Gemcitabine—urinary bladder cancer	0.000638	0.00208	CcSEcCtD
Trimipramine—Hypertension—Etoposide—urinary bladder cancer	0.000637	0.00207	CcSEcCtD
Trimipramine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000633	0.00206	CcSEcCtD
Trimipramine—Eosinophilia—Methotrexate—urinary bladder cancer	0.000628	0.00204	CcSEcCtD
Trimipramine—Insomnia—Fluorouracil—urinary bladder cancer	0.000627	0.00204	CcSEcCtD
Trimipramine—Somnolence—Gemcitabine—urinary bladder cancer	0.000627	0.00204	CcSEcCtD
Trimipramine—Anorexia—Cisplatin—urinary bladder cancer	0.000626	0.00204	CcSEcCtD
Trimipramine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000623	0.00203	CcSEcCtD
Trimipramine—Discomfort—Etoposide—urinary bladder cancer	0.000621	0.00202	CcSEcCtD
Trimipramine—Somnolence—Fluorouracil—urinary bladder cancer	0.000616	0.00201	CcSEcCtD
Trimipramine—Hypotension—Cisplatin—urinary bladder cancer	0.000614	0.002	CcSEcCtD
Trimipramine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000613	0.002	CcSEcCtD
Trimipramine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00061	0.00199	CcSEcCtD
Trimipramine—Fatigue—Gemcitabine—urinary bladder cancer	0.000608	0.00198	CcSEcCtD
Trimipramine—Confusional state—Etoposide—urinary bladder cancer	0.000607	0.00198	CcSEcCtD
Trimipramine—Constipation—Gemcitabine—urinary bladder cancer	0.000603	0.00196	CcSEcCtD
Trimipramine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000603	0.00196	CcSEcCtD
Trimipramine—Pancytopenia—Methotrexate—urinary bladder cancer	0.000602	0.00196	CcSEcCtD
Trimipramine—Asthenia—Thiotepa—urinary bladder cancer	0.000601	0.00196	CcSEcCtD
Trimipramine—Ataxia—Doxorubicin—urinary bladder cancer	0.000597	0.00195	CcSEcCtD
Trimipramine—Pruritus—Thiotepa—urinary bladder cancer	0.000593	0.00193	CcSEcCtD
Trimipramine—Paraesthesia—Cisplatin—urinary bladder cancer	0.00059	0.00192	CcSEcCtD
Trimipramine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.00059	0.00192	CcSEcCtD
Trimipramine—Tachycardia—Etoposide—urinary bladder cancer	0.000588	0.00191	CcSEcCtD
Trimipramine—Eosinophilia—Epirubicin—urinary bladder cancer	0.000588	0.00191	CcSEcCtD
Trimipramine—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000584	0.0019	CcSEcCtD
Trimipramine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000581	0.00189	CcSEcCtD
Trimipramine—Anorexia—Etoposide—urinary bladder cancer	0.000574	0.00187	CcSEcCtD
Trimipramine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000574	0.00187	CcSEcCtD
Trimipramine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000571	0.00186	CcSEcCtD
Trimipramine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000571	0.00186	CcSEcCtD
Trimipramine—Drowsiness—Methotrexate—urinary bladder cancer	0.000565	0.00184	CcSEcCtD
Trimipramine—Pancytopenia—Epirubicin—urinary bladder cancer	0.000564	0.00184	CcSEcCtD
Trimipramine—Hypotension—Etoposide—urinary bladder cancer	0.000563	0.00183	CcSEcCtD
Trimipramine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000557	0.00181	CcSEcCtD
Trimipramine—Dizziness—Thiotepa—urinary bladder cancer	0.000554	0.0018	CcSEcCtD
Trimipramine—Stomatitis—Methotrexate—urinary bladder cancer	0.000551	0.00179	CcSEcCtD
Trimipramine—Urticaria—Fluorouracil—urinary bladder cancer	0.000551	0.00179	CcSEcCtD
Trimipramine—Pollakiuria—Epirubicin—urinary bladder cancer	0.000548	0.00179	CcSEcCtD
Trimipramine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000548	0.00178	CcSEcCtD
Trimipramine—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000544	0.00177	CcSEcCtD
Trimipramine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000542	0.00176	CcSEcCtD
Trimipramine—Paraesthesia—Etoposide—urinary bladder cancer	0.000541	0.00176	CcSEcCtD
Trimipramine—Weight increased—Epirubicin—urinary bladder cancer	0.00054	0.00176	CcSEcCtD
Trimipramine—Somnolence—Etoposide—urinary bladder cancer	0.000535	0.00174	CcSEcCtD
Trimipramine—Vomiting—Thiotepa—urinary bladder cancer	0.000533	0.00174	CcSEcCtD
Trimipramine—Drowsiness—Epirubicin—urinary bladder cancer	0.000529	0.00172	CcSEcCtD
Trimipramine—Rash—Thiotepa—urinary bladder cancer	0.000529	0.00172	CcSEcCtD
Trimipramine—Dermatitis—Thiotepa—urinary bladder cancer	0.000528	0.00172	CcSEcCtD
Trimipramine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000528	0.00172	CcSEcCtD
Trimipramine—Headache—Thiotepa—urinary bladder cancer	0.000525	0.00171	CcSEcCtD
Trimipramine—Decreased appetite—Etoposide—urinary bladder cancer	0.000523	0.0017	CcSEcCtD
Trimipramine—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000522	0.0017	CcSEcCtD
Trimipramine—Body temperature increased—Cisplatin—urinary bladder cancer	0.00052	0.00169	CcSEcCtD
Trimipramine—Fatigue—Etoposide—urinary bladder cancer	0.000519	0.00169	CcSEcCtD
Trimipramine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000519	0.00169	CcSEcCtD
Trimipramine—Stomatitis—Epirubicin—urinary bladder cancer	0.000516	0.00168	CcSEcCtD
Trimipramine—Jaundice—Epirubicin—urinary bladder cancer	0.000516	0.00168	CcSEcCtD
Trimipramine—Constipation—Etoposide—urinary bladder cancer	0.000515	0.00168	CcSEcCtD
Trimipramine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000507	0.00165	CcSEcCtD
Trimipramine—Asthenia—Gemcitabine—urinary bladder cancer	0.000506	0.00165	CcSEcCtD
Trimipramine—Weight increased—Doxorubicin—urinary bladder cancer	0.0005	0.00163	CcSEcCtD
Trimipramine—Pruritus—Gemcitabine—urinary bladder cancer	0.000499	0.00162	CcSEcCtD
Trimipramine—Nausea—Thiotepa—urinary bladder cancer	0.000498	0.00162	CcSEcCtD
Trimipramine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000496	0.00162	CcSEcCtD
Trimipramine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000494	0.00161	CcSEcCtD
Trimipramine—Pruritus—Fluorouracil—urinary bladder cancer	0.00049	0.0016	CcSEcCtD
Trimipramine—Drowsiness—Doxorubicin—urinary bladder cancer	0.00049	0.00159	CcSEcCtD
Trimipramine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000482	0.00157	CcSEcCtD
Trimipramine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.00048	0.00156	CcSEcCtD
Trimipramine—Urticaria—Etoposide—urinary bladder cancer	0.000478	0.00156	CcSEcCtD
Trimipramine—Stomatitis—Doxorubicin—urinary bladder cancer	0.000477	0.00155	CcSEcCtD
Trimipramine—Jaundice—Doxorubicin—urinary bladder cancer	0.000477	0.00155	CcSEcCtD
Trimipramine—Abdominal pain—Etoposide—urinary bladder cancer	0.000476	0.00155	CcSEcCtD
Trimipramine—Body temperature increased—Etoposide—urinary bladder cancer	0.000476	0.00155	CcSEcCtD
Trimipramine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000474	0.00154	CcSEcCtD
Trimipramine—Tinnitus—Methotrexate—urinary bladder cancer	0.000473	0.00154	CcSEcCtD
Trimipramine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000473	0.00154	CcSEcCtD
Trimipramine—Asthenia—Cisplatin—urinary bladder cancer	0.000472	0.00154	CcSEcCtD
Trimipramine—Dizziness—Fluorouracil—urinary bladder cancer	0.000458	0.00149	CcSEcCtD
Trimipramine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000457	0.00149	CcSEcCtD
Trimipramine—Diarrhoea—Cisplatin—urinary bladder cancer	0.00045	0.00146	CcSEcCtD
Trimipramine—Alopecia—Methotrexate—urinary bladder cancer	0.000449	0.00146	CcSEcCtD
Trimipramine—Vomiting—Gemcitabine—urinary bladder cancer	0.000448	0.00146	CcSEcCtD
Trimipramine—Rash—Gemcitabine—urinary bladder cancer	0.000445	0.00145	CcSEcCtD
Trimipramine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000444	0.00145	CcSEcCtD
Trimipramine—Tinnitus—Epirubicin—urinary bladder cancer	0.000443	0.00144	CcSEcCtD
Trimipramine—Headache—Gemcitabine—urinary bladder cancer	0.000442	0.00144	CcSEcCtD
Trimipramine—Flushing—Epirubicin—urinary bladder cancer	0.000441	0.00144	CcSEcCtD
Trimipramine—Vomiting—Fluorouracil—urinary bladder cancer	0.000441	0.00144	CcSEcCtD
Trimipramine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000437	0.00142	CcSEcCtD
Trimipramine—Rash—Fluorouracil—urinary bladder cancer	0.000437	0.00142	CcSEcCtD
Trimipramine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000437	0.00142	CcSEcCtD
Trimipramine—Headache—Fluorouracil—urinary bladder cancer	0.000434	0.00141	CcSEcCtD
Trimipramine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000433	0.00141	CcSEcCtD
Trimipramine—Asthenia—Etoposide—urinary bladder cancer	0.000432	0.00141	CcSEcCtD
Trimipramine—Pruritus—Etoposide—urinary bladder cancer	0.000426	0.00139	CcSEcCtD
Trimipramine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000424	0.00138	CcSEcCtD
Trimipramine—ABCB1—lymph node—urinary bladder cancer	0.000421	0.00268	CbGeAlD
Trimipramine—Alopecia—Epirubicin—urinary bladder cancer	0.00042	0.00137	CcSEcCtD
Trimipramine—Nausea—Gemcitabine—urinary bladder cancer	0.000419	0.00136	CcSEcCtD
Trimipramine—Vomiting—Cisplatin—urinary bladder cancer	0.000418	0.00136	CcSEcCtD
Trimipramine—Vision blurred—Methotrexate—urinary bladder cancer	0.000416	0.00136	CcSEcCtD
Trimipramine—Rash—Cisplatin—urinary bladder cancer	0.000414	0.00135	CcSEcCtD
Trimipramine—Dermatitis—Cisplatin—urinary bladder cancer	0.000414	0.00135	CcSEcCtD
Trimipramine—Diarrhoea—Etoposide—urinary bladder cancer	0.000412	0.00134	CcSEcCtD
Trimipramine—Nausea—Fluorouracil—urinary bladder cancer	0.000412	0.00134	CcSEcCtD
Trimipramine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00041	0.00134	CcSEcCtD
Trimipramine—Tinnitus—Doxorubicin—urinary bladder cancer	0.00041	0.00133	CcSEcCtD
Trimipramine—Flushing—Doxorubicin—urinary bladder cancer	0.000408	0.00133	CcSEcCtD
Trimipramine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000405	0.00132	CcSEcCtD
Trimipramine—Malaise—Methotrexate—urinary bladder cancer	0.000398	0.0013	CcSEcCtD
Trimipramine—Dizziness—Etoposide—urinary bladder cancer	0.000398	0.0013	CcSEcCtD
Trimipramine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000393	0.00128	CcSEcCtD
Trimipramine—Nausea—Cisplatin—urinary bladder cancer	0.00039	0.00127	CcSEcCtD
Trimipramine—Vision blurred—Epirubicin—urinary bladder cancer	0.00039	0.00127	CcSEcCtD
Trimipramine—Alopecia—Doxorubicin—urinary bladder cancer	0.000388	0.00126	CcSEcCtD
Trimipramine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000384	0.00125	CcSEcCtD
Trimipramine—Convulsion—Methotrexate—urinary bladder cancer	0.000383	0.00125	CcSEcCtD
Trimipramine—Vomiting—Etoposide—urinary bladder cancer	0.000383	0.00125	CcSEcCtD
Trimipramine—Agitation—Epirubicin—urinary bladder cancer	0.00038	0.00124	CcSEcCtD
Trimipramine—Rash—Etoposide—urinary bladder cancer	0.00038	0.00124	CcSEcCtD
Trimipramine—Dermatitis—Etoposide—urinary bladder cancer	0.000379	0.00123	CcSEcCtD
Trimipramine—Headache—Etoposide—urinary bladder cancer	0.000377	0.00123	CcSEcCtD
Trimipramine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000375	0.00122	CcSEcCtD
Trimipramine—Malaise—Epirubicin—urinary bladder cancer	0.000373	0.00121	CcSEcCtD
Trimipramine—Discomfort—Methotrexate—urinary bladder cancer	0.000372	0.00121	CcSEcCtD
Trimipramine—Palpitations—Epirubicin—urinary bladder cancer	0.000365	0.00119	CcSEcCtD
Trimipramine—Confusional state—Methotrexate—urinary bladder cancer	0.000364	0.00118	CcSEcCtD
Trimipramine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000361	0.00117	CcSEcCtD
Trimipramine—Convulsion—Epirubicin—urinary bladder cancer	0.000358	0.00117	CcSEcCtD
Trimipramine—Nausea—Etoposide—urinary bladder cancer	0.000358	0.00116	CcSEcCtD
Trimipramine—Hypertension—Epirubicin—urinary bladder cancer	0.000357	0.00116	CcSEcCtD
Trimipramine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000355	0.00116	CcSEcCtD
Trimipramine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000353	0.00115	CcSEcCtD
Trimipramine—Agitation—Doxorubicin—urinary bladder cancer	0.000352	0.00114	CcSEcCtD
Trimipramine—Anxiety—Epirubicin—urinary bladder cancer	0.000351	0.00114	CcSEcCtD
Trimipramine—Discomfort—Epirubicin—urinary bladder cancer	0.000348	0.00113	CcSEcCtD
Trimipramine—Malaise—Doxorubicin—urinary bladder cancer	0.000345	0.00112	CcSEcCtD
Trimipramine—Dry mouth—Epirubicin—urinary bladder cancer	0.000344	0.00112	CcSEcCtD
Trimipramine—Anorexia—Methotrexate—urinary bladder cancer	0.000344	0.00112	CcSEcCtD
Trimipramine—Confusional state—Epirubicin—urinary bladder cancer	0.00034	0.00111	CcSEcCtD
Trimipramine—Palpitations—Doxorubicin—urinary bladder cancer	0.000338	0.0011	CcSEcCtD
Trimipramine—Oedema—Epirubicin—urinary bladder cancer	0.000338	0.0011	CcSEcCtD
Trimipramine—Hypotension—Methotrexate—urinary bladder cancer	0.000337	0.0011	CcSEcCtD
Trimipramine—Convulsion—Doxorubicin—urinary bladder cancer	0.000332	0.00108	CcSEcCtD
Trimipramine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.00033	0.00108	CcSEcCtD
Trimipramine—Hypertension—Doxorubicin—urinary bladder cancer	0.00033	0.00108	CcSEcCtD
Trimipramine—Tachycardia—Epirubicin—urinary bladder cancer	0.000329	0.00107	CcSEcCtD
Trimipramine—Insomnia—Methotrexate—urinary bladder cancer	0.000326	0.00106	CcSEcCtD
Trimipramine—Anxiety—Doxorubicin—urinary bladder cancer	0.000325	0.00106	CcSEcCtD
Trimipramine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000324	0.00105	CcSEcCtD
Trimipramine—Discomfort—Doxorubicin—urinary bladder cancer	0.000322	0.00105	CcSEcCtD
Trimipramine—Anorexia—Epirubicin—urinary bladder cancer	0.000322	0.00105	CcSEcCtD
Trimipramine—Somnolence—Methotrexate—urinary bladder cancer	0.000321	0.00104	CcSEcCtD
Trimipramine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000319	0.00104	CcSEcCtD
Trimipramine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000317	0.00103	CcSEcCtD
Trimipramine—Hypotension—Epirubicin—urinary bladder cancer	0.000315	0.00103	CcSEcCtD
Trimipramine—Confusional state—Doxorubicin—urinary bladder cancer	0.000315	0.00103	CcSEcCtD
Trimipramine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000314	0.00102	CcSEcCtD
Trimipramine—Oedema—Doxorubicin—urinary bladder cancer	0.000312	0.00102	CcSEcCtD
Trimipramine—Fatigue—Methotrexate—urinary bladder cancer	0.000311	0.00101	CcSEcCtD
Trimipramine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000306	0.000996	CcSEcCtD
Trimipramine—Insomnia—Epirubicin—urinary bladder cancer	0.000305	0.000994	CcSEcCtD
Trimipramine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000305	0.000992	CcSEcCtD
Trimipramine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000303	0.000987	CcSEcCtD
Trimipramine—Somnolence—Epirubicin—urinary bladder cancer	0.0003	0.000977	CcSEcCtD
Trimipramine—Anorexia—Doxorubicin—urinary bladder cancer	0.000298	0.000969	CcSEcCtD
Trimipramine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000297	0.000968	CcSEcCtD
Trimipramine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000297	0.000967	CcSEcCtD
Trimipramine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000293	0.000955	CcSEcCtD
Trimipramine—Hypotension—Doxorubicin—urinary bladder cancer	0.000292	0.00095	CcSEcCtD
Trimipramine—Fatigue—Epirubicin—urinary bladder cancer	0.000291	0.000947	CcSEcCtD
Trimipramine—Constipation—Epirubicin—urinary bladder cancer	0.000289	0.00094	CcSEcCtD
Trimipramine—Urticaria—Methotrexate—urinary bladder cancer	0.000287	0.000933	CcSEcCtD
Trimipramine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000285	0.000928	CcSEcCtD
Trimipramine—Body temperature increased—Methotrexate—urinary bladder cancer	0.000285	0.000928	CcSEcCtD
Trimipramine—Insomnia—Doxorubicin—urinary bladder cancer	0.000282	0.00092	CcSEcCtD
Trimipramine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00028	0.000913	CcSEcCtD
Trimipramine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000278	0.000906	CcSEcCtD
Trimipramine—Somnolence—Doxorubicin—urinary bladder cancer	0.000278	0.000904	CcSEcCtD
Trimipramine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000275	0.000895	CcSEcCtD
Trimipramine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000271	0.000884	CcSEcCtD
Trimipramine—Fatigue—Doxorubicin—urinary bladder cancer	0.000269	0.000877	CcSEcCtD
Trimipramine—Urticaria—Epirubicin—urinary bladder cancer	0.000268	0.000873	CcSEcCtD
Trimipramine—Constipation—Doxorubicin—urinary bladder cancer	0.000267	0.00087	CcSEcCtD
Trimipramine—Body temperature increased—Epirubicin—urinary bladder cancer	0.000267	0.000869	CcSEcCtD
Trimipramine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000267	0.000869	CcSEcCtD
Trimipramine—Asthenia—Methotrexate—urinary bladder cancer	0.000259	0.000843	CcSEcCtD
Trimipramine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000257	0.000838	CcSEcCtD
Trimipramine—Pruritus—Methotrexate—urinary bladder cancer	0.000255	0.000831	CcSEcCtD
Trimipramine—Urticaria—Doxorubicin—urinary bladder cancer	0.000248	0.000808	CcSEcCtD
Trimipramine—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000247	0.000804	CcSEcCtD
Trimipramine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000247	0.000804	CcSEcCtD
Trimipramine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000247	0.000803	CcSEcCtD
Trimipramine—Asthenia—Epirubicin—urinary bladder cancer	0.000242	0.000788	CcSEcCtD
Trimipramine—Pruritus—Epirubicin—urinary bladder cancer	0.000239	0.000778	CcSEcCtD
Trimipramine—Dizziness—Methotrexate—urinary bladder cancer	0.000238	0.000777	CcSEcCtD
Trimipramine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000231	0.000752	CcSEcCtD
Trimipramine—Vomiting—Methotrexate—urinary bladder cancer	0.000229	0.000747	CcSEcCtD
Trimipramine—Rash—Methotrexate—urinary bladder cancer	0.000227	0.00074	CcSEcCtD
Trimipramine—Dermatitis—Methotrexate—urinary bladder cancer	0.000227	0.00074	CcSEcCtD
Trimipramine—Headache—Methotrexate—urinary bladder cancer	0.000226	0.000736	CcSEcCtD
Trimipramine—Asthenia—Doxorubicin—urinary bladder cancer	0.000224	0.00073	CcSEcCtD
Trimipramine—Dizziness—Epirubicin—urinary bladder cancer	0.000223	0.000727	CcSEcCtD
Trimipramine—Pruritus—Doxorubicin—urinary bladder cancer	0.000221	0.000719	CcSEcCtD
Trimipramine—Vomiting—Epirubicin—urinary bladder cancer	0.000215	0.000699	CcSEcCtD
Trimipramine—Nausea—Methotrexate—urinary bladder cancer	0.000214	0.000698	CcSEcCtD
Trimipramine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000214	0.000696	CcSEcCtD
Trimipramine—Rash—Epirubicin—urinary bladder cancer	0.000213	0.000693	CcSEcCtD
Trimipramine—Dermatitis—Epirubicin—urinary bladder cancer	0.000213	0.000692	CcSEcCtD
Trimipramine—Headache—Epirubicin—urinary bladder cancer	0.000211	0.000688	CcSEcCtD
Trimipramine—Dizziness—Doxorubicin—urinary bladder cancer	0.000207	0.000672	CcSEcCtD
Trimipramine—Nausea—Epirubicin—urinary bladder cancer	0.0002	0.000653	CcSEcCtD
Trimipramine—Vomiting—Doxorubicin—urinary bladder cancer	0.000199	0.000647	CcSEcCtD
Trimipramine—Rash—Doxorubicin—urinary bladder cancer	0.000197	0.000641	CcSEcCtD
Trimipramine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000197	0.000641	CcSEcCtD
Trimipramine—Headache—Doxorubicin—urinary bladder cancer	0.000196	0.000637	CcSEcCtD
Trimipramine—Nausea—Doxorubicin—urinary bladder cancer	0.000185	0.000604	CcSEcCtD
Trimipramine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	1.46e-05	0.00015	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.46e-05	0.00015	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.46e-05	0.00015	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—ESR1—urinary bladder cancer	1.46e-05	0.000149	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—MMP9—urinary bladder cancer	1.45e-05	0.000149	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling by GPCR—KRAS—urinary bladder cancer	1.45e-05	0.000149	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.45e-05	0.000148	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—CDKN1A—urinary bladder cancer	1.45e-05	0.000148	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—PTEN—urinary bladder cancer	1.45e-05	0.000148	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.44e-05	0.000148	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CREBBP—urinary bladder cancer	1.44e-05	0.000147	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.43e-05	0.000146	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.43e-05	0.000146	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.42e-05	0.000146	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.42e-05	0.000146	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—IGF1—urinary bladder cancer	1.42e-05	0.000145	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—CREBBP—urinary bladder cancer	1.42e-05	0.000145	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—RHOA—urinary bladder cancer	1.41e-05	0.000145	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling by GPCR—EGFR—urinary bladder cancer	1.41e-05	0.000145	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.4e-05	0.000144	CbGpPWpGaD
Trimipramine—HTR1A—Signaling by GPCR—KRAS—urinary bladder cancer	1.4e-05	0.000144	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.4e-05	0.000143	CbGpPWpGaD
Trimipramine—HTR2C—Signaling by GPCR—KRAS—urinary bladder cancer	1.39e-05	0.000143	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—FGFR3—urinary bladder cancer	1.39e-05	0.000143	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.38e-05	0.000141	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—EP300—urinary bladder cancer	1.38e-05	0.000141	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.37e-05	0.000141	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—RHOA—urinary bladder cancer	1.37e-05	0.00014	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.36e-05	0.00014	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.36e-05	0.000139	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—RHOA—urinary bladder cancer	1.36e-05	0.000139	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	1.35e-05	0.000139	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.35e-05	0.000138	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.34e-05	0.000138	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.34e-05	0.000138	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—SRC—urinary bladder cancer	1.34e-05	0.000137	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.34e-05	0.000137	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling by GPCR—KRAS—urinary bladder cancer	1.33e-05	0.000137	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.33e-05	0.000136	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.33e-05	0.000136	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CREBBP—urinary bladder cancer	1.33e-05	0.000136	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—ERBB2—urinary bladder cancer	1.31e-05	0.000134	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—IGF1—urinary bladder cancer	1.31e-05	0.000134	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	1.3e-05	0.000134	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—EGFR—urinary bladder cancer	1.3e-05	0.000133	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	1.3e-05	0.000133	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—RHOA—urinary bladder cancer	1.3e-05	0.000133	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.29e-05	0.000132	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	1.29e-05	0.000132	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.29e-05	0.000132	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	1.28e-05	0.000132	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	1.28e-05	0.000131	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	1.28e-05	0.000131	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	1.28e-05	0.000131	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.27e-05	0.000131	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.26e-05	0.00013	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.26e-05	0.000129	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	1.26e-05	0.000129	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.26e-05	0.000129	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	1.26e-05	0.000129	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	1.25e-05	0.000129	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.25e-05	0.000128	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—CXCL8—urinary bladder cancer	1.24e-05	0.000127	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling by GPCR—HRAS—urinary bladder cancer	1.23e-05	0.000126	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	1.23e-05	0.000126	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.21e-05	0.000124	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	1.21e-05	0.000124	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	1.2e-05	0.000123	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—MYC—urinary bladder cancer	1.2e-05	0.000123	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	1.2e-05	0.000123	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.2e-05	0.000123	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	1.19e-05	0.000122	CbGpPWpGaD
Trimipramine—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.19e-05	0.000122	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.19e-05	0.000122	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—IL2—urinary bladder cancer	1.19e-05	0.000122	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	1.19e-05	0.000122	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	1.19e-05	0.000121	CbGpPWpGaD
Trimipramine—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	1.18e-05	0.000121	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	1.18e-05	0.000121	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	1.18e-05	0.000121	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.18e-05	0.000121	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	1.17e-05	0.00012	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	1.17e-05	0.00012	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	1.17e-05	0.000119	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	1.16e-05	0.000119	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	1.16e-05	0.000119	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	1.16e-05	0.000118	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	1.15e-05	0.000117	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.15e-05	0.000117	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	1.14e-05	0.000117	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	1.14e-05	0.000117	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	1.13e-05	0.000116	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	1.12e-05	0.000115	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.12e-05	0.000115	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	1.12e-05	0.000114	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	1.12e-05	0.000114	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	1.11e-05	0.000114	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	1.11e-05	0.000114	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	1.11e-05	0.000114	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.1e-05	0.000113	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.09e-05	0.000112	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	1.09e-05	0.000112	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	1.09e-05	0.000112	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	1.08e-05	0.000111	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.08e-05	0.000111	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	1.08e-05	0.000111	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	1.08e-05	0.00011	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.07e-05	0.00011	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	1.07e-05	0.00011	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	1.07e-05	0.00011	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.07e-05	0.00011	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	1.06e-05	0.000109	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	1.06e-05	0.000109	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	1.05e-05	0.000108	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.05e-05	0.000107	CbGpPWpGaD
Trimipramine—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	1.05e-05	0.000107	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.04e-05	0.000106	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	1.04e-05	0.000106	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	1.03e-05	0.000106	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	1.03e-05	0.000106	CbGpPWpGaD
Trimipramine—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.03e-05	0.000105	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.03e-05	0.000105	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	1.03e-05	0.000105	CbGpPWpGaD
Trimipramine—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	1.03e-05	0.000105	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	1.03e-05	0.000105	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	1.02e-05	0.000105	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.02e-05	0.000105	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.01e-05	0.000104	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—PTEN—urinary bladder cancer	1.01e-05	0.000104	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.01e-05	0.000103	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—IL2—urinary bladder cancer	1.01e-05	0.000103	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.01e-05	0.000103	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	1e-05	0.000102	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	9.94e-06	0.000102	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	9.93e-06	0.000102	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	9.9e-06	0.000101	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—IL2—urinary bladder cancer	9.88e-06	0.000101	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	9.86e-06	0.000101	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	9.81e-06	0.000101	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	9.81e-06	0.0001	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	9.79e-06	0.0001	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	9.69e-06	9.93e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Metabolism—EP300—urinary bladder cancer	9.66e-06	9.9e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	9.65e-06	9.89e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	9.63e-06	9.87e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	9.62e-06	9.86e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	9.55e-06	9.79e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	9.54e-06	9.78e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	9.52e-06	9.76e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	9.52e-06	9.76e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	9.49e-06	9.72e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	9.46e-06	9.7e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	9.45e-06	9.68e-05	CbGpPWpGaD
Trimipramine—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	9.43e-06	9.67e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	9.42e-06	9.65e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	9.37e-06	9.6e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	9.36e-06	9.59e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	9.35e-06	9.58e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	9.33e-06	9.56e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	9.31e-06	9.54e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	9.31e-06	9.54e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	9.29e-06	9.52e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	9.28e-06	9.51e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	9.24e-06	9.47e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	9.17e-06	9.4e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	9.16e-06	9.39e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	9.14e-06	9.37e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	9.12e-06	9.34e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	9.08e-06	9.3e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—EP300—urinary bladder cancer	9.03e-06	9.25e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	9e-06	9.23e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	8.96e-06	9.18e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	8.91e-06	9.13e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	8.88e-06	9.1e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	8.88e-06	9.1e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—EP300—urinary bladder cancer	8.86e-06	9.08e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	8.78e-06	9e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	8.78e-06	9e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	8.78e-06	8.99e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—SRC—urinary bladder cancer	8.78e-06	8.99e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	8.76e-06	8.98e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	8.72e-06	8.93e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	8.7e-06	8.91e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	8.64e-06	8.85e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—SRC—urinary bladder cancer	8.62e-06	8.83e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	8.57e-06	8.79e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	8.53e-06	8.74e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	8.52e-06	8.73e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	8.49e-06	8.7e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	8.47e-06	8.68e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	8.46e-06	8.67e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	8.41e-06	8.62e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	8.34e-06	8.55e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	8.28e-06	8.48e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	8.25e-06	8.46e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	8.23e-06	8.44e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	8.23e-06	8.43e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	8.08e-06	8.28e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	8.03e-06	8.23e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	7.88e-06	8.08e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—MYC—urinary bladder cancer	7.86e-06	8.06e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	7.86e-06	8.05e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	7.76e-06	7.95e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	7.74e-06	7.93e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—MYC—urinary bladder cancer	7.72e-06	7.91e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	7.69e-06	7.88e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	7.62e-06	7.81e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	7.58e-06	7.77e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	7.57e-06	7.76e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	7.57e-06	7.76e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	7.55e-06	7.74e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	7.5e-06	7.69e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	7.41e-06	7.6e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	7.36e-06	7.54e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	7.32e-06	7.5e-05	CbGpPWpGaD
Trimipramine—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	7.29e-06	7.47e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	7.27e-06	7.45e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—PTEN—urinary bladder cancer	7.18e-06	7.36e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	7.15e-06	7.33e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	7.14e-06	7.31e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	7.04e-06	7.21e-05	CbGpPWpGaD
Trimipramine—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	7.04e-06	7.21e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—PTEN—urinary bladder cancer	7.01e-06	7.18e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	7.01e-06	7.18e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	7e-06	7.17e-05	CbGpPWpGaD
Trimipramine—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	7e-06	7.17e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	6.89e-06	7.06e-05	CbGpPWpGaD
Trimipramine—CYP2C19—Metabolism—EP300—urinary bladder cancer	6.85e-06	7.02e-05	CbGpPWpGaD
Trimipramine—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	6.7e-06	6.87e-05	CbGpPWpGaD
Trimipramine—ABCB1—Metabolism—EP300—urinary bladder cancer	6.68e-06	6.85e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	6.6e-06	6.77e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	6.55e-06	6.71e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	6.51e-06	6.67e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—TP53—urinary bladder cancer	6.46e-06	6.62e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	6.36e-06	6.51e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—TP53—urinary bladder cancer	6.34e-06	6.5e-05	CbGpPWpGaD
Trimipramine—CYP2D6—Metabolism—EP300—urinary bladder cancer	6.3e-06	6.45e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	6.29e-06	6.45e-05	CbGpPWpGaD
Trimipramine—CYP2C9—Metabolism—EP300—urinary bladder cancer	6.24e-06	6.4e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	6.22e-06	6.38e-05	CbGpPWpGaD
Trimipramine—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	6.18e-06	6.33e-05	CbGpPWpGaD
Trimipramine—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	6.08e-06	6.23e-05	CbGpPWpGaD
Trimipramine—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	6.06e-06	6.21e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	6.04e-06	6.19e-05	CbGpPWpGaD
Trimipramine—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	5.95e-06	6.1e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	5.78e-06	5.93e-05	CbGpPWpGaD
Trimipramine—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	5.53e-06	5.67e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.95e-06	5.07e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.32e-06	4.42e-05	CbGpPWpGaD
Trimipramine—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.12e-06	4.22e-05	CbGpPWpGaD
